Acura Pharmaceuticals (Acura Pharmaceuticals) Cash-to-Debt : 0.33 (As of Dec. 2021)

View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Acura Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2021 was 0.33.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Acura Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2021.

The historical rank and industry rank for Acura Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ACUR's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.945
* Ranked among companies with meaningful Cash-to-Debt only.

Acura Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Acura Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acura Pharmaceuticals Cash-to-Debt Chart

Acura Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

0.82

0.02

0.14

0.07

0.33

Acura Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Cash-to-Debt	Get a 7-Day Free Trial															0.07	0.06	0.28	0.28	0.33

Competitive Comparison of Acura Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acura Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Cash-to-Debt falls into.

Acura Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Acura Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.065	/	(0.033	+	0.167)
	=	0.33

Acura Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.065	/	(0.033	+	0.167)
	=	0.33

Acura Pharmaceuticals (OTCPK:ACUR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Acura Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

616 N. North Court, Suite 120, Palatine, IL, USA, 60067

Website

http://www.acurapharm.com

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

Executives

Bruce F Wesson	director	1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly	director	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross	director	1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh	officer: VP, Corporate Development
Immanuel Thangaraj	director	10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser	officer: VP, Treasurer & Controller	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones	officer: President & CEO	C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko	officer: VP Pharmaceutical Sciences APT	C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens	officer: Senior VP & CFO	C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc	10 percent owner	333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc	10 percent owner	C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte	10 percent owner	9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P	10 percent owner	610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc	10 percent owner	680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp	10 percent owner	610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020